We assessed the non-inferiority of accelerated fractionation (AF) (2.4 Gy/fraction) compared with standard fractionation (SF) (2 Gy/fraction) regarding progression-free survival (PFS) in patients with T1-2N0M0 glottic cancer (GC).
Introduction
Definitive radiotherapy (RT) is considered a standard treatment of early glottic cancer (GC) that allows excellent voice preservation without sacrificing life expectancy [1, 2] . Standard fractionated (SF) RT, defined as 66-70 Gy over 7 weeks, is still usually used [3, 4] . As for head and neck cancer (HNC), prolongation of RT may worsen local control due to so-called 'accelerated tumour clonogen repopulation during RT', which can lead to resistance [5] . Although several reports have shown a clinical advantage for altered fractionated RT, the optimal schedule has not been determined [6] .
The advantage of accelerated fractionation (AF) over hyperfractionated RT is that single daily fractions allow convenient access and shorten the overall treatment time (OTT), which may positively impact locoregional control by overcoming accelerated repopulation. Further, AF also reduces medical costs, frequency of patient visits, equipment burden, and staff labor. We considered AF to be an attractive way to ensure a minimal treatment period with an acceptable frequency of acute adverse events (AEs) for GC patients with early stage disease. However, the increased dose fraction size of AF RT may increase the probability of late toxicity.
The majority of previous prospective and retrospective studies that discussed the efficacy of AF for GC [1, 4, [7] [8] [9] used fractions of 2-2.25 Gy. We selected the relatively larger fraction size of 2.4 Gy with the aim of a more optimal advantage in reducing OTT for GC. Two prospective trials for various type of HNC reported that the AF arm with 12-12.6 Gy/week which corresponds to the fraction size of 2.4 Gy showed sufficiently better local control with acceptable toxicity than that of SF arm, and a weekly dose of 12 Gy seemed the maximum tolerable dose for toxicity [6, 10] . In fact, there were two retrospective analyses that reported a fraction of 2.4 Gy showed most promising efficacy with lower toxicity for GC patients [11, 12] . In addition, the selection of 2.4 Gy fraction size was supported by the estimate of biologically effective dose (BED) which was comparable to that of 2 Gy arm (supplementary Table S1 , available at Annals of Oncology online) [13] .
We accordingly deemed a fraction of 2.4 Gy administered 5 times a week to be the most promising. In 2007, the Radiation Therapy Study Group (RTSG) of the Japan Clinical Oncology Group (JCOG) initiated a phase III study, JCOG0701, for patients with early GC that compared an AF arm with 2.4 Gy per fraction to an SF arm with 2 Gy per fraction. The AF arm in this study used a slightly higher dose fraction, with the aim of reducing OTT for GC, which was not used in prior prospective trials [14] . The overall aim of the JCOG0701 trial was to confirm the non-inferiority of the efficacy of AF compared with that of SF. Here, we report the primary efficacy results from this multiinstitutional randomized controlled trial (RCT) for early GC using AF.
Methods
Detail of method can be referred to method sup.
Study design and participants
Patients with histologically confirmed squamous cell carcinoma of the glottis were eligible. All patients were diagnosed with T1 or T2 (no impaired cord morbidity) N0M0 disease. It was required on registration that radiation therapy was expected to be completed within the recommended duration without interruption due to national holidays. Other inclusion criteria were: age 20-80 years, Eastern Cooperative Oncology Group performance status 0-1, no previous surgery or RT, and no previous cancer or additional current cancers. Patients were required to have sufficient organ function.
Pre-registration workup included blood examination to show sufficient organ function, laryngoscopy, chest X-ray, and CT scans of the pharynx and neck with contrast media. The study protocol was reviewed and approved by the Protocol Review Committee of JCOG and the institutional review board at each institution. All patients provided written informed consent.
Randomization and masking
Patients were randomly assigned in a 1 : 1 ratio to the SF or AF arm at the JCOG Data Center, using a minimization method with biased-coin assignment balancing on T stage (T1 versus T2) and institution.
Procedure
All patients underwent a dose-planning CT scan. The gross tumour volume was determined based on laryngoscopic and CT findings. The clinical target volume (CTV) included the vocal cords for T1 lesions, and the vocal cords with a 1 cm margin for T2 lesions. The planning target volume included the CTV with both a 0.5-1 cm margin and laryngeal motion. Details of radiation field definition were summarized in supplementary Figure S1 , available at Annals of Oncology online. Linear accelerators were used to deliver photon beams of 3-6 MV.
Dose fractionation schedule for the AF arm was determined based on the estimate of biologically effective dose (BED) (supplementary Table S1 , available at Annals of Oncology online) [13] . We used corrected BED (cBED) to accurately estimate efficacy, including the effect of OTT [15] . The SF arm received 66/70 Gy for T1/T2 lesions. The AF arm patients received 60/64.8 Gy in 2.4 Gy/fr for T1/T2 lesions. BED estimates for tumour response (cBED) and late responding tissue (BED Gy 3 ) of the two arms were comparable.
Follow up was intended every 6 weeks to 6 months after completion of treatment, followed by every 3 months afterwards. At each follow-up, patients were examined with a laryngoscope and cervical lymph nodes palpation. Laryngoscopic images were acquired at initial enrolment and a mean of 6 weeks (61 week) after the completion of RT. If a complete response (CR) was not achieved, laryngoscopy was repeated every 4 weeks until it detected CR or progressive disease. Biopsy was carried out for histological confirmation when laryngoscopy findings suggested local recurrence.
Outcomes
The primary end point was the proportion of 3-year PFS. Secondary end points were overall survival (OS), local progression-free survival (LPFS), disease-free survival (DFS), survival with preserved voice function (PVFS), complete response rate, proportion of treatment completion within the recommended duration, and AEs. All time-to-event end points were measured from randomization to the date of the event or censoring. A PFS event was defined by any recurrence or death from any cause; OS by death from any cause; LPFS by laryngeal progression or death from any cause; DFS by secondary cancer, any recurrence, or death from any cause; and PVFS by a voice change of grade !3 or death from any cause.
Treatment completion was defined as the completion of protocol treatment within 51/53 days for T1/T2 disease for the SF arm, and within 39/43 days for the AF arm.
AEs were graded using the Common Terminology Criteria for Adverse Events v 3.0 (CTCAE).
Statistical analysis
The trial was designed to demonstrate that AF RT is not inferior to SF RT in terms of the proportion of 3-year PFS for all randomized patients. Expected 3-year PFS in the SF/AF arm was 80/85%. The planned sample size was 360 patients with a one-sided alpha of 5%, power of 80% and a non-inferiority margin of 5% for the primary end point. Ineligible patients, however, were more numerous than expected; thus the sample size was increased to 370 patients to ensure a power of 80%. Two planned interim analyses were conducted after registration of half of the expected patients, and after the completion of protocol treatment of the last accrued patient. Multiplicity was adjusted using the Southwest Oncology Group method for each analysis [16] , under which the one-sided alpha was 0.5% at each interim analysis and 4.5% at final analysis.
All efficacy analyses were done in the intention-to-treat population. The primary analysis of 3-year PFS was carried out by the method of Dunnet-Gent [2] . As for the primary analysis, patients censored within 3 years of randomization were considered as having experienced a worstcase event. The other statistics of time-to-event end points were estimated using the Kaplan-Meier (K-M) method. Hazard ratios (HR) were estimated by Cox's proportional hazard model. Safety analyses were conducted in the groups, excluding untreated or group-converted.
As post hoc analyses to explore details of first failure among PFS events, time to death, time to laryngeal failure, and time to distant and/or regional lymph node metastasis were estimated by the cumulative incidence approach with the failure types other than the first failure type as competing risks. Additionally, time to laryngeal failure (local control rate: LCR) was estimated by the K-M method with death as a censored event.
All statistical analyses were carried out using SAS 9.2 or more (SAS Institute, Cary NC). This study is registered with UMIN-CTR, number UMIN000000819.
Results
A total of 184 patients were randomized to the SF arm and 186 patients to the AF arm from 5 September 2007 to 25 January 2013. The CONSORT flow diagram of JCOG0701 is shown in Figure 1 . All these patients were entered into an intention-totreat analysis for efficacy. Ineligible patients included patients with a T3 lesion (N ¼ 1), active double cancers (N ¼ 2) and inadequate scheduling (N ¼ 1) in the SF arm (N ¼ 4) , and active double cancers (N ¼ 2), active double cancers and having an N2cM1 lesion (N ¼ 1), and inadequate scheduling (N ¼ 1) in the AF arm (N ¼ 4). Two and one patients in each arm did not receive protocol treatment and one patient in the AF arm converted into the SF arm. These three patients were excluded from safety analysis. In addition, 5/1 patients from the SF/AF arm, were excluded from the safety analysis of acute AEs due to missing data, leaving 177/183 patients for the SF/AF arm (Figure 1 ). Median follow-up period of all registered patients was 4.8 (interquartile range: 3.4-6.2) years. Table 1 shows patient characteristics. Background factors were well balanced in the two arms.
As the primary end point of this trial, the proportion of 3-year PFS in the SF arm was 79.9% (95% confidence interval [CI] 73.4% to 85.4%), while that of the AF arm was 81.7% (95% CI 75.4% to 87.0%). The difference in 3-year PFS between the SF and AF arms was 1.8% (91% CI À5.1% to 8.8%); thus, the noninferiority of AF could not be confirmed, as the lower bound of CI, À5.1%, failed to exceed the non-inferiority margin of À5.0% (one-sided P for non-inferiority ¼ 0.047 > 0.045, which is the multiplicity-adjusted alpha level). Figure 2 shows the PFS Kaplan-Meier curve.
The 3-year OS by the K-M method was 98.4% (95% CI 95% to 99.5%)/93.5% (95% CI 88.9% to 96.3%) for the SF/AF arm (supplementary Figure S2 , available at Annals of Oncology online). Causes of death are shown in supplementary Table S2 , available at Annals of Oncology online. More patients died of other diseases, especially secondary cancers, in the AF arm. The number of deaths before any recurrence was 8/11 in the SF/AF arms. Five (2.7%) and 8 (4.3%) patients in the SF and AF arm died of the disease. The cumulative incidence of death at 3 years was 0.5%/ 3.3% in the SF/AF arm (supplementary Figure S3A , available at Annals of Oncology online).
In the SF arm, local progression developed in 28 (16.6%) of 169 surviving patients and 6 (40.0%) of 15 dead patients. In the AF arm, local progression developed in 16 (9.8%) of 164 surviving patients and 4 (18.2%) of 22 dead patients. The cumulative incidence of local failure at 3 years in the SF/AF arm was 15.9%/10.3% (supplementary Figure S3B , available at Annals of Oncology online). In post hoc analyses, time to laryngeal failure (LCR) was also calculated for comparison with the results of prior series. In this analysis, the SF arm showed a worse 3-year LCR compared with the AF arm (83.0%-89.5%).
Distant and regional lymph node metastasis proportions were 1.1%/3.3% for the SF/AF arm (supplementary Figure S3C , available at Annals of Oncology online).
Among the groups for intention-to-treat analysis, 12 (3.2%) patients did not meet the defined criteria for treatment completion. A total of 175 patients (95.1%) and 183 patients (98.4%) in the SF and AF arms received protocol treatment according to their respective planned schedules.
Supplementary Table S3 , available at Annals of Oncology online, summarizes the incidence of all AEs in both arms. The incidence of grade 3/4 acute AEs was 22/0 in the SF arm, and 21/1 in the AF arm. No grade 3 dysphagia, pain, or edema of the larynx occurred in either arm. No treatment related death developed in both arms.
The incidence of grade 3/4 late AEs was 1/2 in the SF arm, and 1/0 in the AF arm.
Discussion
Among the strengths of the present trial is that it is the first completed multi-institutional RCT for early GC. Further, it used a relatively large fraction of 2.4 Gy; use of larger fractions maximises the advantage of a shortened OTT. Although the non-inferiority of AF was not confirmed, both efficacy regarding local disease progression and AEs were comparable between the arms.
We compared our results with those of two previous RCTs of AF with 2.25 Gy for GC, which showed LCR was better with AF than SF [8, 9] . In the first RCT, a single-institutional Japanese trial [9] , the SF arm consisted of 60-66 Gy, while the AF arm consisted of 56.25-63 Gy. Five-year LCR was significantly better in the AF arm (92% versus 77%, P ¼ 0.004).
The second RCT that evaluated AF with 2.25 Gy fractions was KROG 0201, a multi-institutional Korean trial [8] . Although 282 patients were expected to be enrolled, the trial ended prematurely due to slow accrual (N ¼ 156). The radiation schedules for T1/T2 lesions were 66/70 Gy in the SF arm and 63/67.5 Gy in the AF arm. In that trial, the 5-year LPFS proportion of the SF/AF arms was 78%/89%.
In these two studies, LCR in the SF arm seemed relatively lower compared with that of other reported series (supplementary Table S4 , available at Annals of Oncology online), including our study (83% for the T1-2 group). Neither of the above RCTs reported the OTT, and defined protocol completion regarding treatment duration. We suppose that SF could have had a longer OTT compared to AF and that the decreased LCR might be explained by potential prolongation inversely impacting the results of the SF arm [3] . One of the reasons that non-inferiority was not confirmed in our study may be based on the fact that we set strict limitations regarding treatment duration.
Another reason for the failure to confirm non-inferiority was the slightly lower incidence of death in the SF arm. We expected that PFS of the AF arm would be better than that of the SF arm by 5%, but the actual gain in 3-year PFS of AF was slightly less than the expected value of 5%. Initially we estimated the death proportion in both arms to be 3% at 3 years, but, it was actually 0.5%/ 3.3% in the SF/AF arm. At 3 years, as of the primary analysis, 1/8 patients had died of other causes in the SF/AF arms, of whom 1/6 died of secondary cancers. The unexpected imbalance in early death from secondary cancers might have inversely impacted the primary end point. In fact, LCR at 3 years (post hoc analysis) in the AF arm was significantly better than that in the SF arm (89.5%/83.0%). One limitation of this study is its relatively short follow-up of 3 years to evaluate late toxicities. Any late AEs of grade !3 developed with sufficiently low incidence at least during the three years of follow-up, compared with these previously reported series [17] (supplementary Table S4 , available at Annals of Oncology online). In addition, the completion proportions of RT with a strictly limited OTT of both arms were sufficiently robust (95.1% for SF, 98.4% for AF), although a larger fraction dose size increases the probability of AEs. In this trial, acute AEs in the two arms proved to be reasonably comparable with those in other RCTs [8, 9] . We therefore conclude that AF using a 2.4 Gy fraction did not significantly worsen any AEs.
Since the AF arm failed to confirm non-inferiority to the SF arm, the SF arm, with 2 Gy per fraction for early GC, is still considered standard therapy. However, the PFS of the AF arm was slightly superior to that of SF arm and there were apparent clinical advantages of AF, namely a reduction in patient visits, medical staff workload, and medical costs. Thus, we believe AF is also a treatment option for early GC.
In conclusion, the similar efficacy and toxicity of AF to SF as well as its practical convenience indicate that AF has potential as a treatment option for early GC. Years after randomisation 5 6 7 8 9 Figure 2 . Progression-free survival curves of both arms. SF, standard fractionation; AF, accelerated fractionation.
